P3 Health Partners Inc

P3 Health Partners, Inc. is a population health care management company, which engages in the provision of professional support services to doctors and clinicians. The firm offers capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences. The company was founded by Sherif Abdou and Amir Bacchus on August 20, 2020 and is headquartered in Henderson, NV.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

P3 Health Partners Inc reports robust Q4 performance and eyes profitability in 2024

P3 Health Partners Inc demonstrated strong financial performance and strategic initiatives during the Q4 2022 earnings call, positioning the company for future growth and profitability. While facing challenges in managing costs and optimizing margins, the company remains optimistic about its financial outlook and growth prospects. By leveraging opportunities in market expansion and operational enhancements, P3 Health Partners Inc aims to achieve positive cash flow in 2024.

P3 Health Partners Inc reports improved Q1 performance and growth outlook

P3 Health Partners Inc showed improved financial performance and operational metrics in Q1.
The company is on track towards profitability, with a focus on growth and healthcare transformation.
Challenges include managing EBITDA losses, COVID impact, and provider relationships.
Opportunities lie in further improving metrics, expanding in newer markets, and enhancing care management.

P3 Health Partners Inc reports strong Q2 earnings and growth opportunities

P3 Health Partners Inc (PIII) demonstrated positive financial performance in Q2 2023, with strong revenue growth and improved margins.
The company's focus on operational efficiency, quality improvements, and growth objectives positions it well for future success.
While facing challenges in managing expenses and achieving profitability, P3 Health Partners Inc (PIII) has opportunities for growth and market expansion.
Overall, the company's sustained demand, efficient operations, and progress towards profitability indicate a promising outlook for stakeholders.

P3 Health Partners Inc reports solid Q3 results, eyes growth

P3 Health Partners Inc delivered a strong performance in Q3, focusing on revenue growth, cost management, and profitability.
While facing challenges such as timing issues and payer negotiations, the company remains optimistic about its future prospects.
Opportunities for growth include expanding partnerships, optimizing operational efficiency, and providing clearer financial guidance to stakeholders.
Overall, PIII's strategic initiatives position it well for continued success, with a positive outlook for 2024 and beyond.

P3 Health Partners reports strong 2023 growth and positive 2024 outlook

P3 Health Partners Inc delivered robust financial performance in 2023.
Strategic initiatives led to improved margins and revenue growth.
Challenges include managing expenses and potential regulatory changes.
Opportunities lie in partnerships, persistency rates, and revenue expansion.

P3 Health Partners reports strong Q1 earnings, eyes AI growth

P3 Health Partners Inc's Q1 2024 showed strong revenue growth and operational efficiencies.
The company is confident in achieving its EBITDA guidance through strategic partnerships and focus on high-risk populations.
Challenges include managing cash flow, capital requirements for growth, and effective high-risk population management.
Opportunities lie in AI partnerships, data analytics tools, and deeper provider engagement for better care outcomes.

P3 Health Partners reports robust Q2 results and eyes growth

P3 Health Partners showed strong performance in Q2 with revenue growth, cost reduction, and improved EBITDA loss. The company's focus on expense management and balance sheet strength position it well for future growth. Challenges remain in managing medical costs and achieving profitability, but opportunities for expansion and improved financial performance are evident.

P3 Health Partners reports Q3 loss, plans improvements for 2025

P3 Health Partners Inc faced challenges in Q3 2024 with a $71 million adjusted EBITDA loss, driven by retroactive adjustments and high medical utilization. Despite this, the company plans significant improvements in contracts, efficiency, and data analytics for 2025. Opportunities exist in optimizing working capital, strategic financing, and focusing on high-performance markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (Nasdaq: PIII), a patient-centered and physician-led population health management company (the “Company”), today announced that it has entered into definitive agreements to sell securities in a private placement with a group of institutional investors. The lead institutional investors in the private placement are affiliates of Chicago Pacific Founders (“CPF”) and Leavitt Partners.

P3 Health Partners Inc. Announces Approximately $90 Million Private Placement

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announced that it will now release results for fourth-quarter 2022 and full-year ended December 31, 2022 on Friday, March 31, 2023 before the market open.

P3 Health Partners Announces Date Change for Fourth-Quarter and Full-Year 2022 Earnings Call

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that the Company expects to release its financial results for fourth-quarter 2022 and full-year ended December 31, 2022 and file its Annual Report on Form 10-K on Thursday, March 30, 2023.

P3 Health Partners to Report Fourth-Quarter and Full-Year 2022 Financial Results on March 30

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it expects to file the Company's Annual Report on Form 10-K on or before the close of business on March 30th, 2023 and that it plans to host an Earnings Call to review those results following the market close on the same day.

P3 Health Partners Affirms 2023 Outlook and Schedules Earnings Call for 2022 Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that Dr. Amir Bacchus, co-founder and Chief Medical Officer, will be participating in a fireside chat at the upcoming Jefferies Value-Based Care Summit in Miami Beach, FL on March 13, 2023. Dr. Bacchus will be participating at 2:45PM Eastern Time. Dr.

P3 Health Partners Executive to Present at Upcoming Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, announces that Dr. Sherif Abdou, P3's co-founder and Chief Executive Officer, is scheduled to present at the TD Cowen 43rd Annual Health Care Conference in Boston on Tuesday, March 7, 2023 at 1:30 pm Eastern Time. A live audio webcast of the presentation is available here.

P3 Health Partners CEO to Present at Upcoming Investor Conference

P3 Health Partners' guidance breaks the billion-dollar mark in 2022 revenues. P3 Health Partners anticipates that its Adjusted EBITDA will be positive in 2024.

P3 Health Partners Reaffirms 2022 Growth Over 61% And Path To Profitability

P3 Health Partners has had a good quarter with the top line growing 59% YoY. The future looks bright as the management remains confident in opening another 20 facilities.

P3 Health Partners Inc. Could Be A Good Play Eventually

Alset EHome International

CymaBay Therapeutics

Fate Therapeutics

Hall of Fame Resort & Entertainment

Century Therapeutics

Avidity Biosciences

Summit Therapeutics

Trean Insurance Group

Viking Therapeutics

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

HENDERSON, Nev.--( BUSINESS WIRE )--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, is participating in J.P. Morgan's 41st Annual Healthcare Conference, being held in San Francisco, CA from January 9-12, 2023. In advance of the associated presentation, P3 is reaffirming full-year 2022 financial guidance and announcing financial guidance for the full-year 2023.

P3 Health Partners Reaffirms Guidance For 2022 and Announces Guidance For 2023

HENDERSON, Nev.--( BUSINESS WIRE )-- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, is participating in J.P. Morgan's 41st Annual Healthcare Conference, to be held in San Francisco, CA from January 9-12, 2023.

P3 Health Partners to Present at the 41st Annual J.P. Morgan Healthcare Conference

HENDERSON, Nev.--( BUSINESS WIRE )--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced Atul Kavthekar will be joining the Company as Chief Financial Officer (CFO), on December 12, 2022.

P3 Health Partners Names Atul Kavthekar Chief Financial Officer

P3 Health Partners Inc. (NASDAQ:PIII ) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Karen Blomquist - Vice President of Investor Relations Sherif Abdou - Chief Executive Officer Erin Darakjian - Interim Chief Financial Officer Amir Bacchus - Co-Founder and Chief Medical Officer Conference Call Participants Joshua Raskin - Nephron Research Brooks O'Neil - Lakes Treat Gary Taylor - Cowen Operator Greetings, and welcome to P3 Health Partners Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

P3 Health Partners Inc. (PIII) Q3 2022 Earnings Call Transcript

HENDERSON, Nev.--( BUSINESS WIRE )--P3 Health Partners, Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter and nine months ended September 30, 2022.

P3 Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results

HENDERSON, Nev.--( BUSINESS WIRE )--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company expects to release its financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022. In connection with this announcement, management will host a conference call and provide a corporate and financial update. Details for the conference call are as follows.

P3 Health Partners to Present Third Quarter 2022 Financial Results

P3 Health Partners Announces Participation in Credit Suisse Healthcare Conference

P3 Health Partners Announces Nasdaq's Confirmation that it has Regained Compliance with Listing Requirements

P3 Health Partners Inc. (NASDAQ:PIII ) Q2 2022 Earnings Conference Call October 20, 2022 4:30 PM ET Company Participants Karen Blomquist - Vice President, Investor Relations Sherif Abdou - Chief Executive Officer Eric Atkins - Chief Financial Officer Amir Bacchus - Chief Medical Officer Erin Darakjian - Chief Accounting Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Josh Raskin - Nephron Research Ryan Daniels - William Blair Gary Taylor - Cowen & Company Operator Greetings. Welcome to P3 Health Partners' First Half 2022 Earnings Conference Call.

P3 Health Partners Inc. (PIII) Q2 2022 Earnings Call Transcript

HENDERSON, Nev., Oct. 20, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners, Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter and six months ended June 30, 2022.

P3 Health Partners Provides Second-Quarter and Year-to-Date 2022 Financial Results; Increases 2022 Revenue Outlook

HENDERSON, Nev., Oct. 20, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced the resignation of Chief Financial Officer, Eric Atkins, effective November 1, 2022. Mr. Atkins has taken a position in Denver to pursue a business opportunity that will allow him to be closer to family.

P3 Health Partners Announces Chief Financial Officer Transition Appoints Erin Darakjian as Interim CFO

Management to Host Conference Call and Webcast

P3 Health Partners to Present 1H 2022 Financial Results

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that on September 28, 2022 it received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from

P3 Health Partners Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its Chief Executive Officer, Dr. Sherif Abdou, will participate on the “Next Frontier – Value Based Care for Sub-Capitation/Specialties” virtual panel at the Nephron 2nd Annual Physician Enablement Symposium on Thursday, September 22nd at 9:00 am EDT. About P3 Health Partners (NASDAQ: PIII): P3 Health Partners Inc. is a leadi

P3 Health Partners CEO Dr. Sherif Abdou to Speak at Nephron 2nd Annual Physician Enablement Symposium

TUCSON, Ariz.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that P3 Health Partners, LLC dba P3 Health Partners-Arizona (“P3 Arizona”) has acquired the practice of Dr. Leonardo Serfino, M.D., in Sierra Vista, Ariz. Dr. Serfino, who specializes in internal medicine, will continue to support his existing patients, as well as accept new Medicare Advantage patients. Dr. Serfino and his staf

P3 Arizona Announces New Medical Clinic in Cochise County, Arizona

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that P3 Health Partners-Nevada, LLC (“P3 Nevada”) has named Allen Pate as president. Pate will lead the P3 Nevada Medical Group team to continue ensuring that its 20,000 Medicare Advantage patients within Clark and Nye Counties receive the best possible care through P3 Nevada's expansive network of more than 400 primary care

News for P3 Health Partners Inc Stock (PIII)